Answers are grounded in this paper and cite their sources.
Myocarditis has been associated with a wide range of infectious agents. Some microrganisms have a cardiomyocyte tropism, whereas for others, such as Parvovirus B19 (PVB19), the myocardial cellular target is represented by endothelial cells [1,2]. Nevertheless, a vasculitis of the intramural coronary vessels caused by PVB19 has never been described. We report a case of fatal myocarditis and small vessel vasculitis related to a PVB19-Toxoplasma gondii co-infection in an HIV-positive patient, clinically mimicking an acute myocardial infarction. Case report A 45-year-old woman was admitted because of chest pain and dyspnoea. Electrocardiogram revealed atrial fibrillation (160 bpm mean rate) with diffuse ST-segment elevation and T-wave inversion. Echocardiography showed moderate dilation with severe global left ventricular hypokinesia (ejection fraction 0.25). The myocardial type isoenzyme fraction of creatine kinase was 223 U/l (normal value < 10 U/l) and the troponin I level was 6 ng/ml (normal value < 0.05 ng/ml). Unpredictably, coronary angiography showed a normal coronary network. On the basis of a persistent marked lymphocytopenia (CD4 cells 76/μl, CD8 cells 1566/μl, CD4: CD8 ratio 0.05) a serological assay for HIV antibodies was performed, which gave a positive result. The HIV-RNA plasma level was greater than 500 000 copies/ml. Serology showed a positivity for PVB19 and T. gondii IgG, whereas no evidence of active infection was detected. Despite full medical therapy with diuretics, angiotensin-converting enzyme inhibitors and digitalis, the patient's clinical condition worsened and cardiac function progressively deteriorated (ejection fraction 0.15). Ten days after admission the patient died as a result of cardiac arrest. Microscopic evaluation of the heart revealed diffuse lymphocytic myocarditis, with a predominance of CD8 cells, diffusely infiltrating both the myocardium and intramural vessels (Fig. 1a). Cardiomyocytes were focally swollen by intracytoplasmic cysts containing trophozoites of T. gondii (Fig. 1b). Polymerase chain reaction analysis confirmed the presence of Toxoplasma DNA and demonstrated the presence of the PVB19 genome (Fig. 1c), whereas it was negative for other cardiotropic viruses. Polymerase chain reaction on blood samples was negative for PVB19 and T. gondii. Immunohistochemistry for PVB19 antigen showed the presence of granular intracytoplasmic staining in the endothelial cells of intramural vessels, more evident in those surrounded by severe inflammatory infiltrates (Fig. 1d), and was negative in other cell types.Fig. 1: Microscopic evaluation and polymerase chain reaction analysis of the heart, from the patient. (a) Cardiomyocytes and intramyocardial vessel infiltration by CD8 lymphocytes (immunoperoxidase, 400×). (b) Prominent lymphocytic infiltrates around myocytes that focally contain cysts of Toxoplasma gondii (arrow; haematoxylin and eosin 250×). (c) Nested polymerase chain reaction analysis using primers designed to amplify a 102 base pair sequence of PVB19. Lane 1, serum from the patient; lane 2, myocardium; lane 3, negative control (no template); lane 4, PVB19-positive control; lane 5, molecular weight marker. (d) Granular intracytoplasmic positivity of VP1 and VP2 PVB19 antigens (cloneR92F6; Novocastra, Newcastle, UK) in endothelial cells of intramyocardial vessels, surrounded by inflammatory infiltrates (immunoperoxidase 250×).A previously undescribed myocardial inflammation caused by T. gondii and PVB19 co-infection has been reported. The major contribution of T. gondii was related to its direct mechanism of cardiomyocyte damage, as documented by the presence of intracytoplasmic cysts. Conversely, PVB19 infection affected endothelial cells, as shown by their strong positivity for viral antigens, leading to vasculitis of the intramural vessels. The synergic action of the two agents caused a severe and rapidly progressive myocardial inflammation, mimicking the clinical phenotype of an acute myocardial infarction. T. gondii is the most frequent protozoan causing opportunistic infections in immunocompromised individuals, and has been observed in up to 12% of HIV patients at necropsy [3]. Occasionally, Toxoplasma myocarditis can occur in association with other infectious agents, but, as far as we know, co-infection with PVB19 has never been described. Human PVB19 is a DNA virus member of the family of Parvoviridae, and is emerging as a new agent associated with myocarditis, dilated cardiomyopathy and isolated diastolic dysfunction [1,2]. This agent has also been detected in serum and tissue samples of patients with systemic vasculitis syndromes [4]. In our patient, the presence of the PVB19 genome in the myocardium associated with the positivity for viral antigens on endothelial cells and the absence of serological evidence of an acute PVB19 infection suggests that the virus entered the cells during a previous asymptomatic infection and persisted in the latent phase for many years, until unknown factors, possibly immunodepression, induced transcriptional activity of PVB19, resulting in acute symptomatic disease. The immunocompromised state could explain the occurrence of a previously undescribed severe vasculitis of the intramyocardial vessels, leading to endothelial dysfunction and impairment of coronary microcirculation simulating ischaemic heart disease. Moreover, PVB19 antigens can induce an immune-mediated reaction with the release of proinflammatory cytokines and secondary myocyte necrosis and inflammation [5]. The prominent lymphocytic infiltrates of both myocytes and vessels, which are unusual for isolated Toxoplasma myocarditis, support this hypothesis and a relevant pathogenetic role for PVB19 infection. Toxoplasmosis infection can receive a specific treatment with confirmed clinical good results even in immunocompromised patients [3]. Moreover, PVB19-associated vasculitis has been successfully treated with intravenous immunoglobulin therapy [4]. An early diagnosis by endomyocardial biopsy and molecular biology studies, with the prompt institution of a specific anti-infectious treatment, might have prevented the fatal course of myocardial infection. The study was supported by the grant EX ART.56 entitled “HIV-related and unrelated inflammatory cardiomyopathy: identification of causal agents and pathogenetic mechanisms providing a tailored therapy.
No takes yet. Share an insight, caveat, or question.
Chimenti et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: